Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 3, 2013, Pages 523-531

  Ylikangas, Henna ^a   Peura, Lauri ^a   Malmioja, Kalle ^a   Leppänen, Jukka ^a   Laine, Krista ^a   Poso, Antti ^a   Lahtela Kakkonen, Maija ^a   Rautio, Jarkko ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Large neutral amino acid transporter 1 (LAT1); Pharmacophore; Prodrug; Structure activity relationships

Indexed keywords

AMINO ACID TRANSPORTER; DRUG CARRIER; LARGE AMINO ACID TRANSPORTER 1; UNCLASSIFIED DRUG; CARBON; LEUCINE; LIGAND; NERVE PROTEIN; NOOTROPIC AGENT; PRODRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN PERFUSION; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG DESIGN; HYDROGEN BOND; HYDROPHOBICITY; MALE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; KINETICS; METABOLISM; NERVE CELL; PERFUSION; TRANSPORT AT THE CELLULAR LEVEL; VALIDATION STUDY; WISTAR RAT;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; BRAIN; CARBON RADIOISOTOPES; HYDROGEN BONDING; KINETICS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LEUCINE; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NERVE TISSUE PROTEINS; NEURONS; NOOTROPIC AGENTS; PERFUSION; PRODRUGS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872367616     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.11.014     Document Type: Article

References (42)

1. Boado, R.J., Li, J.Y., Nagaya, M., Zhang, C., Pardridge, W.M., 1999. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc. Nat. Acad. Sci. USA 96, 12079-12084.
2. Bonina, F.P., Arenare, L., Palagiano, F., Saija, A., Nava, F., Trombetta, D., de Caprariis, P., 1999. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J. Pharm. Sci. 88, 561-567.
3. Chang, C., Swaan, P.W., 2006. Computational approaches to modeling drug transporters. Eur. J. Pharm. Sci. 27, 411-424.
4. Christensen, H.N., 1990. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol. Rev. 70, 43-77.
5. ConfGen, v. 2.3., Schrodinger, LLC, New York, 2011.
6. Cundy, K.C., Branch, R., Chernov-Rogan, T., Dias, T., Estrada, T., Hold, K., Koller, K., Liu, X., Mann, A., Panuwat, M., Raillard, S.P., Upadhyay, S., Wu, Q.Q., Xiang, J., Yan, H., Zerangue, N., Zhou, C.X., Barrett, R.W., Gallop, M.A., 2004. XP13512 [(±)-1-([(a-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther. 311, 315-323.
7. del Amo, E.M., Urtti, A., Yliperttula, M., 2008. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur. J. Pharm. Sci. 35, 161-174.
8. Deves, R., Krupka, R.M., 1979. The binding and translocation steps in transport as related to substrate structure: A study of the choline carrier of erythrocytes. Biochim. Biophys. Acta 557, 469-485.
9. Dixon, S.L., Smondyrev, A.M., Knoll, E.H., Rao, S.N., Shaw, D.E., Friesner, R.A., 2006a. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20, 647-671.
10. Dixon, S.L., Smondyrev, A.M., Rao, S.N., 2006b. PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chem. Biol. Drug Des. 67, 370-372.
11. Epik, v. 2.2., Schrodinger, LLC., New York, 2011.
12. Eyal, S., Hsiao, P., Unadkat, J.D., 2009. Drug interactions at the blood-brain barrier: Fact or fantasy? Pharmacol. Ther. 123, 80-104.
13. Fan, X., Ross, D.D., Arakawa, H., Ganapathy, V., Tamai, I., Nakanishi, T., 2010. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: A possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. Biochem. Pharmacol. 80, 811-818.
14. Goldenberg, G.J., Lam, H.Y., Begleiter, A., 1979. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J. Biol. Chem. 254, 1057-1064.
15. Gomes, P., Soares-da-Silva, P., 1999. L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Res. 829, 143-150.
16. Gynther, M., Jalkanen, A., Lehtonen, M., Forsberg, M., Laine, K., Ropponen, J., Leppanen, J., Knuuti, J., Rautio, J., 2010. Brain uptake of ketoprofen-lysine prodrug in rats. Int. J. Pharm. 399, 121-128.
17. Gynther, M., Laine, K., Ropponen, J., Leppanen, J., Mannila, A., Nevalainen, T., Savolainen, J., Jarvinen, T., Rautio, J., 2008. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J. Med. Chem. 51, 932-936.
18. Hawkins, R.A., O'Kane, R.L., Simpson, I.A., Vina, J.R., 2006. Structure of the blood-brain barrier and its role in the transport of amino acids. J. Nutr. 136, 218S-26S.
19. Irwin, J.J., Shoichet, B.K., 2005. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model 45, 177-182.
20. Jorgensen, W.L., Tirado-Rives, J., 1988. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J. Am. Chem. Soc. 110, 1657-1666.
21. Killian, D.M., Hermeling, S., Chikhale, P.J., 2007. Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system. Drug Deliv. 14, 25-31.
22. Kim, C.S., Cho, S.H., Chun, H.S., Lee, S.Y., Endou, H., Kanai, Y., Kim do, K., 2008. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol. Pharm. Bull. 31, 1096-1100.
23. Leach, A.R., Gillet, V.J., Lewis, R.A., Taylor, R., 2010. Three-dimensional pharmacophore methods in drug discovery. J. Med. Chem. 53, 539-558.
24. Liang, Z., Cho, H.T., Williams, L., Zhu, A., Liang, K., Huang, K., Wu, H., Jiang, C., Hong, S., Crowe, R., Goodman, M.M., Shim, H., 2011. Potential biomarker of L-type amino acid transporter 1 in breast cancer progression. Nucl. Med. Mol. Imaging 45, 93-102.
25. Pardridge, W.M., 2005. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2, 3-14.
26. Pardridge, W.M., 1983. Brain metabolism: A perspective from the blood-brain barrier. Physiol. Rev. 63, 1481-1535.
27. Pavan, B., Dalpiaz, A., 2011. Prodrugs and endogenous transporters: Are they suitable tools for drug targeting into the central nervous system? Curr. Pharm. Des. 17, 3560-3576.
28. Peura, L., Malmioja, K., Laine, K., Leppanen, J., Gynther, M., Isotalo, A., Rautio, J., 2011. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: New prodrug design ideas for central nervous system delivery. Mol. Pharm. 8, 1857-1866.
29. Phase, v. 3.3., Schrodinger, LLC, New York, 2011.
30. Sakata, T., Ferdous, G., Tsuruta, T., Satoh, T., Baba, S., Muto, T., Ueno, A., Kanai, Y., Endou, H., Okayasu, I., 2009. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol. Int. 59, 7-18.
31. Shelley, J.C., Cholleti, A., Frye, L.L., Greenwood, J.R., Timlin, M.R., Uchimaya, M., 2007. Epik: A software program for pKa prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21, 681-691.
32. Shennan, D.B., Thomson, J., 2008. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol. Rep. 20, 885-889.
33. Smith, Q.R., 2005. Carrier-mediated transport to enhance drug delivery to brain. Int. Congr. Ser. 1277, 63-74.
34. Smith, Q.R., Allen, D.D., 2003. In situ brain perfusion technique. Methods Mol. Med. 89, 209-218.
35. Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G.F., Faller, B., Fischer, H., Gerebtzoff, G., Lennernaes, H., Senner, F., 2010. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9, 597-614.
36. Sybyl-X, v. 1.2., Tripos International, 1699 South Hanley Rd., St. Louis, Missouri 63144, USA.
37. Takada, Y., Vistica, D.T., Greig, N.H., Purdon, D., Rapoport, S.I., Smith, Q.R., 1992. Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res. 52, 2191-2196.
38. Takasato, Y., Rapoport, S.I., Smith, Q.R., 1984. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247, H484-H493.
39. Toth, G., Bowers, S.G., Truong, A.P., Probst, G., 2007. The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance. Curr. Pharm. Des. 13, 3476-3493.
40. Uchino, H., Kanai, Y., Kim, D.K., Wempe, M.F., Chairoungdua, A., Morimoto, E., Anders, M.W., Endou, H., 2002. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol. Pharmacol. 61, 729-737.
41. van Bree, J.B., Audus, K.L., Borchardt, R.T., 1988. Carrier-mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture. Pharm. Res. 5, 369-371.
42. Watts, K.S., Dalal, P., Murphy, R.B., Sherman, W., Friesner, R.A., Shelley, J.C., 2010. ConfGen: A conformational search method for efficient generation of bioactive conformers. J. Chem. Inf. Model. 50, 534-546.